Isomorphic Labs, the London-based drug discovery company spun out of Alphabet's DeepMind, said on November 17, 2026, that it raised $5 billion in a Series C funding round. Greenoaks and Sequoia Capital led the round, with Alphabet, Andreessen Horowitz, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participating. The company did not disclose a new valuation, but the raise follows a $2.1 billion Series B, pushing its disclosed total funding past $7 billion in under two years.
What does Isomorphic Labs actually build?
Isomorphic Labs runs a system it calls the Isomorphic Drug Design Engine, or IsoDDE, built on foundation models descended from DeepMind's protein-structure research. Instead of screening existing chemical libraries for hits, the engine generates candidate molecules from scratch and predicts how they will bind to a target protein before any lab synthesis takes place.
Founder and chief executive Demis Hassabis, who also runs Google DeepMind, said the engine is generating molecules with what he called unprecedented precision and speed. President Max Jaderberg said the models are producing weekly, repeatable improvements in molecular profiles. The company reports positive preclinical results in oncology and immunology programs, with internal and partnered candidates now progressing toward clinical entry, according to the announcement carried by PR Newswire.
Why does a drug-discovery company need $5 billion?
Designing a molecule on a computer is cheap compared with proving it works in a human body. Isomorphic Labs says the new capital will mature IsoDDE, extend the models into new areas of biology and drug modalities, and build what it calls global infrastructure for AI-led bioengineering. A large share is earmarked for translational and clinical development infrastructure, the expensive, slow part of drug-making that AI shortens on the design side but cannot skip entirely.
That marks a shift in what Isomorphic Labs is: not just a software vendor licensing predictions to pharmaceutical partners, but a company now funding its own path to clinical trials, with the balance sheet of a mid-size biotech rather than an AI lab.
How does this compare with other AI drug discovery rounds?
Most AI-driven drug discovery startups have raised in the hundreds of millions, not billions. Isomorphic Labs' $5 billion Series C dwarfs typical rounds in the sector and even exceeds the total funding many publicly traded biotech companies have raised over a decade. Its advantage is lineage: the company's models trace directly back to DeepMind's AlphaFold protein-structure breakthroughs, giving it a head start that newer entrants, built on open-source models or licensed structure predictions, are still trying to replicate.
What should the industry watch next?
The next real test for Isomorphic Labs is not funding size but clinical results. Watch for its first investigational new drug filings, any new pharmaceutical partnership announcements, and whether its oncology and immunology candidates clear early-phase trials. A $5 billion round buys time and infrastructure; it does not guarantee a drug reaches patients.